secwatch.observer — SEC 8-K summary
======================================

Issuer:     OMEROS CORP (OMER)
CIK:        0001285819
Form:       8-K
Filed at:   2021-11-09T23:59:59+00:00
Accession:  0001558370-21-015276
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Omeros Q3 OMIDRIA rev $30M (+4.1% QoQ); net loss narrows; FDA CRL for narsoplimab
--------------------------------------------------------------------------------

- OMIDRIA revenue $30.0M in Q3, up 4.1% from Q2 $28.8M; driven by ASC growth.
- Net loss $22.7M ($0.36/sh) improved from $28.6M ($0.46/sh) in Q2; cash $50.4M.
- CMS confirmed separate payment for OMIDRIA in ASC for 2022; NOPAIN Act has 34 Senate/74 House sponsors.
- Received FDA Complete Response Letter for narsoplimab BLA in HSCT-TMA; preparing Type A meeting.
- Phase 1 data for OMS906 shows high alternative pathway suppression; moving directly into PNH patients.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1285819/000155837021015276/0001558370-21-015276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1285819/000155837021015276/omer-20211109x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-21-015276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer